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Several studies have suggested that diabetes mellitus (DM) increases the risk of active
tuberculosis (TB). The rising prevalence of DM in TB-endemic areas may adversely affect TB
control. We conducted a systematic review and a meta-analysis of observational studies
assessing the association of DM and TB in order to summarize the existing evidence and to
assess methodological quality of the studies.
Methods and Findings
We searched the PubMed and EMBASE databases to identify observational studies that had
reported an age-adjusted quantitative estimate of the association between DM and active TB
disease. The search yielded 13 observational studies (n¼1,786,212 participants) with 17,698 TB
cases. Random effects meta-analysis of cohort studies showed that DM was associated with an
increased risk of TB (relative risk ¼ 3.11, 95% CI 2.27–4.26). Case-control studies were
heterogeneous and odds ratios ranged from 1.16 to 7.83. Subgroup analyses showed that
effect estimates were higher in non-North American studies.
Conclusion
DM was associated with an increased risk of TB regardless of study design and population.
People with DM may be important targets for interventions such as active case finding and
treatment of latent TB and efforts to diagnose, detect, and treat DM may have a beneficial
impact on TB control.
The Editors’ Summary of this article follows the references.
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PLoS MEDICINEIntroduction
Despite the availability of effective therapy, tuberculosis
(TB) continues to infect an estimated one-third of the world’s
population, to cause disease in 8.8 million people per year,
and to kill 1.6 million of those afﬂicted [1]. Current TB control
measures focus on the prompt detection and treatment of
those with infectious forms of the disease to prevent further
transmission of the organism. Despite the enormous success of
this strategy in TB control, the persistence of TB in many parts
of the world suggests the need to expand control efforts to
identify and address the individual and social determinants of
the disease. Since the early part of the 20th century, clinicians
have observed an association between diabetes mellitus (DM)
and TB, although they were often unable to determine
whether DM caused TB or whether TB led to the clinical
manifestations of DM [2–6]. Furthermore, these reports did
not address the issues of confounding and selection bias. More
recently, multiple rigorous epidemiological studies investigat-
ing the relationship have demonstrated that DM is indeed
positively associated with TB [7–11]. While the investigators
suggested that the association reﬂects the effect of DM on TB,
some controversy over the directionality of the association
remains due to observations that TB disease induces tempo-
rary hyperglycemia, which resolves with treatment [12,13]. A
causal link between DM and TB does not bode well for the
future, as the global burden of DM is expected to rise from an
estimated 180 million prevalent cases currently to a predicted
366 million by 2030 [14]. Experts have raised concerns about
the merging epidemics of DM and TB [15–17], especially in
low- to middle-income countries, such as India and China, that
are experiencing the fastest increase in DM prevalence [18]
and the highest burden of TB in the world [19]. Given the
public health implications of a causal link between DM and
TB, there is a clear need for a systematic assessment of the
association in the medical literature. We undertook a system-
atic review to qualitatively and quantitatively summarize the
existing evidence for the association between DM and TB, to
examine the heterogeneity underlying the different studies,
and to evaluate the methodological quality of the studies. As
our aim was to summarize the effect of DM on TB, we did not
include studies that investigated the reverse association.
Methods
We conducted our systematic review according to the
guidelines set forth by the Meta-analysis of Observational
Studies in Epidemiology (MOOSE) group for reporting of
systematic reviews of observational studies (see Text S2 for
the MOOSE Checklist) [20].
Search Strategy and Selection Criteria
We searched the PubMed database from 1965 to March
2007 and the EMBASE database from 1974 to March 2007 for
studies of the association between DM and TB disease; our
search strategy is detailed in Box 1. We also hand-searched
bibliographies of retrieved papers for additional references
and contacted experts in the ﬁeld for any unpublished
studies. Since we speculated that studies that examined the
association between DM and TB may not have referred to the
term ‘‘diabetes’’ in the title or abstract, we also searched for
studies that examined any risk factors for active TB. We
restricted our analysis to human studies, and placed no
restrictions on language. We included studies if they were
peer-reviewed reports of cohort, case-control, or cross-
sectional studies that either presented or allowed computa-
tion of a quantitative effect estimate of the relationship
between DM and active TB and that controlled for possible
confounding by age or age groups. We also included studies
that compared prevalence or incidence of DM or TB of an
observed population to a general population as long as they
had performed stratiﬁcation or standardization by age
groups. We excluded studies if they were any of the following:
case studies and reviews; studies among children; studies that
did not provide effect estimates in odds ratios, rate ratios, or
risk ratios, or did not allow the computation of such; studies
that did not adjust for age; studies that employed different
methods for assessing TB among individuals with and without
DM or for assessing DM among TB patients and controls;
studies that investigated the reverse association of the impact
of TB disease or TB treatment on DM; anonymous reports;
and duplicate reports on previously published studies.
Box 1. Search Strategy to Identify Observational Studies on the





3. ‘‘cohort studies’’ OR ‘‘case-control studies’’ OR ‘‘cross-sectional
studies’’ OR ‘‘epidemiologic studies’’ OR ‘‘follow-up studies’’ OR




2. ‘‘diabetes’’ OR ‘‘glucose intolerance’’ OR ‘‘glucose tolerance’’ OR
‘‘insulin resistance’’
3. ‘‘chronic disease(s)’’ OR ‘‘non-communicable disease(s)’’
4. ‘‘risk factor(s)’’
Search strings (all inclusive):
1. 1 AND 2
2. 1 AND 3 AND 5
3. 1 AND 3 AND 6
4. 1 AND 3 AND 7
5. 4 AND 5 (for the year preceding 3/2/07 for articles that may not have
been assigned MeSH terms)
EMBASE
Text terms
1. ‘‘tuberculosis’’, major subject
2. ‘‘diabetes mellitus’’
3. ‘‘risk factor(s)’’
4. ‘‘observational study’’ OR ‘‘longitudinal study’’ OR ‘‘prospective
study’’ OR ‘‘case-control study’’ OR ‘‘cross-sectional study’’
Search strings (all inclusive):
1. 1 AND 2
2. 1 AND 3
3. 1 AND 4
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The two investigators (CJ, MM) independently read the
papers and extracted information on the year and country of
the study, background TB incidence, study population, study
design, number of exposed/unexposed people or cases/
controls, deﬁnitions and assessment of DM and TB, statistical
methods, effect estimates and their standard errors, adjust-
ment and stratiﬁcation factors, response rates, the timing of
diagnosis of DM relative to that of TB, and the potential
duplication of data on the same individuals. Differences were
resolved by consensus. For the studies that did not directly
report the background TB incidence, we obtained data for
the closest matching year and state (or country) made




We separated the studies by study design and assessed
heterogeneity of effect estimates within each group of studies
using the Cochrane Q test for heterogeneity [21] and the I
2
statistic described by Higgins et al. [22]. We determined the
95% conﬁdence intervals (CIs) for the I
2 values using the test-
based methods [22]. We performed meta-analysis for compu-
tation of a summary estimate only for the study design (i.e.,
cohort) that did not show signiﬁcant heterogeneity. Effect
estimates of other study designs were not summarized due to
signiﬁcant heterogeneity. For those studies that reported age,
sex, race, or region stratum-speciﬁc effects, we calculated an
overall adjusted effect estimate for the study using the
inverse-variance weighting method, then included this
summary estimate in the meta-analyses and sensitivity
analyses. We decided a priori to use the Dersimonian and
Laird random effects method to pool the effect estimates
across studies for the meta-analyses, because the underlying
true effect of DM would be expected to vary with regard to
underlying TB susceptibility and the severity of DM, and
because it would yield conservative 95% conﬁdence intervals
[23].
In order to identify possible sources of heterogeneity and
Figure 1. Flow Chart of Literature Search for Studies on the Association between Diabetes Mellitus and Active Tuberculosis
doi:10.1371/journal.pmed.0050152.g001
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Diabetes and Tuberculosis Reviewto assess the effect of study quality on the reported effect
estimates, we performed sensitivity analyses in which we
compared pooled effect estimates for subgroups categorized
by background TB incidence, geographical region, under-
lying medical conditions of the population under study, and
the following quality-associated variables: time of assessment
of DM in relation to TB diagnosis, method of DM assessment
(self-report or medical records versus laboratory tests),
method of TB assessment (microbiologically conﬁrmed versus
other), adjustment for important potential confounders, and
the potential duplication of data on the same individuals. To
determine whether the effect estimates varied signiﬁcantly by
the above-mentioned factors, we performed univariate meta-
regressions, in which we regressed the study-speciﬁc log-
transformed relative risks (RRs) by the variables representing
the study characteristics, weighting the studies by the inverse
of the sum of within-study and between-study variance for all
studies within the comparison. For background TB incidence,
we created an ordinal variable, 1 representing , 10/100,000
person-years to 3 representing   100/100,000 person-years.
Coefﬁcients of meta-regression represent differences in log-
transformed RRs between the subgroups; we tested the
signiﬁcance of these coefﬁcients by Student t-test, and
signiﬁcance was set at p , 0.10. We considered studies to be
of higher quality if they speciﬁed that DM be diagnosed prior
to the time of TB diagnosis; used blood glucose tests for
diagnosis of DM; used a microbiological deﬁnition of TB;
adjusted for at least age and sex; were cohort, nested case-
control, or population-based case-control studies; or did not
have the potential for duplication of data. As the average
Table 1. Summary of the 13 Observational Studies of Association between Diabetes and Active Tuberculosis Included in the Meta-
analysis





Kim et al., 1995 [7] South Korea, civil servants 1988–1990 306
John et al., 2001 [32] India, renal transplant patients in Vellore 1986–1999 168
c
Chen et al., 2006 [30] Taiwan, renal transplant recipients in Taichung 1983–2003 66.7
Case-control Mori et al., 1992 [34] US, Oglala Sioux Indians in South Dakota 1986 90.9
Buskin et al., 1994 [35] US, residents seen at TB clinic in Washington 1988–1990 9
Rosenman and Hall 1996 [36] US, male residents registered at New Jersey
Department of Health
Jan 1985, May 1987 9.5




Brassard et al., 2006 [31] US, PharMetrics Database with  1 prescription
for antirheumatic medication
September 1998–December 2003 5.6
Coker et al., 2006 [37] Russia, residents in the city of Samara January 2003–December 2003 118
c
Jick et al., 2006 [33] UK, General Practice Research Database 1990–2001 3
Perez et al., 2006 [11] US Residents of 15 Texas/Mexico border
counties (based on discharge records)
1999–2001 13.1
Other
d Ponce-de-Leon et al., 2004 [9] Mexico, civilians in Veracruz March 1995–April 2003 for TB case
accrual; 2005 for diabetes survey
28
Dyck et al., 2007 [25] Canada, registered Indians and other
Saskatchewans
January 1986–December 2001 for TB case
accrual; January 1991–December 1995 for
diabetes survey
44
aBackground incidence of TB per 100,000 person-years.
bStratum-specific RRs were pooled by inverse-variance weighting method.
cData obtained from external source.
dOther: Neither the study by Ponce-de-Leon et al. [9] or by Dyck et al. [25] were specified as prospective cohort, or case-control study. TB case accrual was conducted prospectively, while
the underlying distribution of diabetes was determined from a separate registry during a period of time after the start of case accrual.
AFB, acid-fast bacilli stain; BMI, body mass index; CDC 1990, 1990 Case Definition for Tuberculosis by Center for Disease Control (US): http://www.cdc.gov/ncphi/disss/nndss/casedef/
tuberculosis_1990.htm; CMV, cytomegalovirus; FBG, fasting blood glucose; ICD-9, International Statistical Classification of Diseases and Related Health Problems 9th edition; PCP,
pneumocystis pneumonia; PPBG, postprandial blood glucose; NSAID, non-steroidal anti-inflammatory drug.
doi:10.1371/journal.pmed.0050152.t001
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Diabetes and Tuberculosis Reviewbackground incidence rate of TB did not exceed 2 per 100
person-years in any of the of the case-control studies that had
not employed incidence density sampling, we assumed TB to
be sufﬁciently rare that the odds ratios would estimate the
risk ratios [24], and that it would therefore be valid to
compute summary RR in the sensitivity analyses regardless of
the measure of association and design of the study.
We explored possible effect modiﬁcation by age by
examining the three studies that reported results by age
groups [7,9,25]. For this analysis, we graphed the stratum-
speciﬁc estimates in a forest plot, and tested for hetero-
geneity of the effects within each study by the Q-test and I
2
value. We also performed meta-regression within each study
in which we regressed the log-transformed RRs by the mid-
points of the age-bands. For the unbound age group,   60 y,
we added half the range of the neighboring age-band, or 5 y,
to the cutoff. We computed the factor reduction in RR with
10 y increases in age, and reported the p-value for signiﬁcance
of trend.
We assessed publication bias using the Begg test and Egger
test [26,27]. Statistical procedures were carried out using R
version 2.5.1 [28]. 95% CI of the I
2 value was computed using
the ‘‘heterogi’’ module in STATA version 10 [29].
Results
We identiﬁed and screened 3,701 papers by titles and
abstracts; of these, 3,378 were excluded because they did not
study risk factors for TB, were studies among children, were
case reports, reviews, or studies of TB treatment outcome
(Figure 1). Of the remaining 323 articles, 232 studies were
excluded because they did not report on the association
between DM and TB, and 56 studies were excluded because
they were review articles (12) or ecological studies (2); studied
the clinical manifestations of TB in people with diabetes (11);
studied the association of DM and TB treatment outcome (6);
assessed latent, relapsed, clustered, or drug-resistant TB as
the outcome (6); studied the reverse association of the effect
of TB on DM (5); had no comparison group (5); were case
reports (3); did not give a quantitative effect estimate (3); had
collapsed DM and other chronic diseases into a single
covariate (2); or was a study that had been reported elsewhere
(1). We contacted the authors of four papers that reported
including DM in a multivariate analysis but that did not
provide the adjusted effect estimate for DM; we included the
papers of the two authors who responded and provided these
adjusted estimates [30,31]. Further exclusion of studies that
Table 1. Extended.
Exposure Outcome Adjusted Variables
DM diagnosed as  119 mg/dl at screening,
followed by FBG  150 mg/dl and PPBG  
180 mg/dl
Pulmonary TB determined by X-ray Age
b
DM diagnosed as FBG .120 mg/dl or
PPBG .200 mg/dl; or two elevated levels
of either measurement
All TB diagnosed by X-ray, AFB, gastric juice,
bronchoalveolar specimen, or culture of affected
tissue
Age, chronic liver disease, other coexisting infections (CMV,
PCP, nocardia, deep mycoses), immunosuppressive medications
DM diagnosis from medical chart All TB diagnosed by (1) positive culture, (2) presence
of granuloma in biopsy, (3) typical chest X-ray finding,
or (4) clinical presentation consistent with TB and
favorable response to treatment
Age, sex, dialysis duration, HBV and HCV infection, graft
rejection .3, immunosuppressive medications
DM determined by antidiabetic treatment;
or  11.1 mmol/l at screening or  7.8
mmol/l FBG
Clinically diagnosed TB, not otherwise specified Age, sex, alcohol abuse, isoniazid therapy, residence
DM by self-report All TB defined by CDC 1990 Age
DM by self-report All TB diagnosed by positive culture, or physician’s
diagnosis with anti-TB medication
Age, sex, race
DM from medical chart coded as
ICD-9 250.0–250.9
All TB coded as ICD-9 010–018 Age, sex, race
b, poor education, median income, health
insurance, HIV-related conditions, chronic renal insufficiency,
alcohol-related conditions, drug use
DM from medical chart coded as
ICD-9 250.0–250.9
All TB coded as ICD-9 010–018 Age, sex, silicosis, chronic renal failure, hemodialysis, solid
organ transplant, head and neck cancer, NSAIDs, steroids,
Cox-2 inhibitors
DM by self-report Pulmonary TB diagnosed by positive culture Age, sex, relative with TB, drinking raw milk, assets, number of
cohabiting persons, employment, smoking, alcohol, financial
security, illicit drugs, history of imprisonment
DM determined by antidiabetic treatment All TB treated with anti-TB medication Age, sex, index date, amount of computerized medical history,
glucocorticoid use, smoking, BMI, pulmonary disease, use of
anti-rheumatic or immunosuppressive agents
DM from medical chart coded as
ICD-9: 250.0 - 250.9
All TB coded as ICD-9 010–018 Age, sex, race, insurance, chronic renal failure, nutrition
deficiency, income, education, residence at border
b
DM previously diagnosed by a physician;
or FBG   126 mg/dl or  200 mg/dl for
random samples
All TB diagnosed by positive AFB or positive culture Age
b, and standardized by sex
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Diabetes and Tuberculosis Reviewdid not adjust for age (11), studies that used a general
population as the comparison group for TB incidence or DM
prevalence without standardization by age (9), and studies
that used different methods for ascertaining TB in the people
with diabetes and control group (2), left 13 eligible studies.
These included three prospective cohort studies [7,30,32],
eight case-control studies [8,11,31–37], and two studies for
which study design could not be classiﬁed as either cohort or
case control, as TB case accrual occurred prospectively while
the distribution of diabetes in the population was assessed
during a different time period after baseline [9,25]. The
studies were set in Canada (1), India (1), Mexico (1), Russia (1),
South Korea (1), Taiwan (1), the UK (1), and the US (6), and
were all reported in English and conducted in the last 15 y.
Two of the cohort studies were among renal transplant
patients [30,32], and three of the case-control studies were
hospital-based or based on discharge records [8,11,35]. The
studies are summarized in Table 1.
Figure 2 summarizes the adjusted effect estimates of the 13
studies categorized by the study design. We found substantial
heterogeneity of effect estimates from studies within each
study design; between-study variance accounted for 39% of
the total variance among cohort studies, 68% of the total
variance among case-control studies, and 99% of the total
variance in the remaining two studies. Despite this hetero-
geneity, the forest plot shows that DM is positively associated
with TB regardless of study design, with the exception of the
study by Dyck et al. [25]. DM was associated with a 3.11-fold
(95% CI 2.27–4.26) increased risk of TB in the cohort studies.
Of note, the study conducted within a nontransplant
population provided greater weight (63%) to the summary
estimate than the other two cohort studies combined. The
effect estimates in the remaining studies were heterogeneous
and varied from a RR of 0.99 to 7.83.
Table 2 shows that there is an increased risk of active TB
among people with diabetes regardless of background
incidence, study region, or underlying medical conditions
in the cohort. In the sensitivity analyses, we noticed that the
strength of association increased from a RR of 1.87 to a RR of
3.32 as background TB incidence of the study population
increased from , 10/100,000 person-years to   100/100,000
person-years, but the trend was not signiﬁcant (trend p ¼
0.229). Effect estimates were heterogeneous within each
category of background TB incidence (I
2 ¼ 60%, 98%, and
76% from highest to lowest background TB incidence
category).
We also found that the associations of DM and TB in the
study populations from Central America [9], Europe [33,37],
and Asia [7,30,32] (RRCentralAm ¼6.00, RREurope¼4.40, RRAsia ¼
3.11) were higher than those of North American studies
[8,11,33,34–36] (RRNA ¼ 1.46) (meta-regression pCentralAm ¼
0.006, pEurope ¼ 0.004, pAsia ¼ 0.03). Among North American
studies, the pooled estimate of the relative risks for Hispanics
from two studies [8,11] was higher (RR ¼ 2.69) than that of
non-Hispanics from the same study [8] and other North
American studies (RR ¼ 1.23) (meta-regression p ¼ 0.060)
(Table 2).
In general, stratiﬁcation of the studies by quality-associated
variables did not reduce the heterogeneity of effect estimates.
Nonetheless, DM remained positively associated with TB in
all strata. Studies that explicitly reported that DM was
diagnosed prior to TB showed stronger associations (RR ¼
2.73) [7,31–34] than those that did not establish the temporal
order of DM and TB diagnosis (RR ¼ 2.10) [8,9,11,25,30,35–
Figure 2. Forest Plot of the 13 Studies That Quantitatively Assessed the Association between Diabetes and Active Tuberculosis by Study Designs
Size of the square is proportional to the precision of the study-specific effect estimates, and the bars indicate the corresponding 95% CIs. Arrows
indicate that the bars are truncated to fit the plot. The diamond is centered on the summary RR of the cohorts studies, and the width indicates the
corresponding 95% CI. *Other: The studies by Ponce-de-Leon et al. [7] and Dyck et al. [25] were not specified as prospective cohort or case-control. TB
case accrual occurred prospectively, while the underlying distribution of diabetes was determined during a different time period after baseline.
doi:10.1371/journal.pmed.0050152.g002
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Diabetes and Tuberculosis Review37], although the difference was not signiﬁcant (meta-
regression p ¼ 0.483). Associations were stronger in studies
that classiﬁed DM exposure through empirical testing (RR ¼
3.89) [7,9,32,34] rather than medical records (RR ¼ 1.61)
(meta-regression p ¼ 0.051) [8,11,25,30,31,33]; and in those
that conﬁrmed TB status using microbiological diagnosis (RR
¼ 4.91) [7,9,35,37] than in the studies that did not conﬁrm by
microbiological tests (RR ¼ 1.66) (meta-regression p ¼ 0.015)
[8,11,25,30–34,36]. Among case-control studies, those that
were nested in a clearly identiﬁable population or were
population-based also reported stronger associations (RR ¼
3.36) [31,33,34,37] than those that used hospital based
controls (RR ¼ 1.62) [8,11,37], but the difference was not
signiﬁcant (meta-regression p ¼ 0.321). Studies that had
adjusted for smoking showed stronger associations (RR ¼
4.40) [33,37], while studies in which an individual may have
contributed more than one observation to the data revealed
weaker associations (RR ¼ 1.62) [8,11]. Although these results
suggest that higher-quality studies gave stronger estimates of
association, we also found that the association was weaker in
studies that adjusted for socioeconomic status (RR ¼ 1.66)
(Table 2) [8,11,37].
Figure 3 presents the summary measures of the association
between DM and TB by age group based on the data from the
three studies that presented age-stratiﬁed RRs. The plots
from Kim et al. [7] and Ponce-de-Leon et al. [9] demonstrate
stronger associations of DM and TB under the age of 40 y and
declining RR with increasing age in age groups over 40 y

























 100 (3) 3.32 2.13–5.17 60% 0%–89% 0.081 0.229
 10 and ,100 (6) 2.22 1.42–3.48 98% 96%–98% ,0.001 —
,10 (4) 1.87 1.09–3.20 76% 34%–91% 0.006 —
Region Central America (1) 6.00 5.00–7.20 N/A N/A N/A 0.006
Europe (2) 4.40 2.49–7.79 17% 0%–57% 0.272 0.004
Asia (3) 3.11 2.27–4.26 39% 0%–81% 0.196 0.030
All North America (7) 1.46 1.25–1.71 74% 43%–88% 0.001 Ref
North America: Hispanics (2)
e 2.69 2.27–3.19 80% 13%–95% 0.026 0.060
f
North America: American Indians (2)
g 1.85 0.34–10.19 82% 23%–96% 0.019 0.913
f
North America: non-Hispanics, non-
American Indians (5)
1.23 1.13–1.32 0% 0%–79% 0.488 Ref
f
Underlying conditions Transplant or arthritis patients (3) 1.86 1.28–2.70 44% 0%–83% 0.169 0.688
Quality
assessment
DM pre-dated TB Explicitly stated (5) 2.73 1.68–4.44 89% 77%–95% ,0.001 0.483
Unclear (8) 2.10 1.41–3.12 97% 95%–98% ,0.001 —
DM diagnosis Laboratory test (4) 3.89 2.52–6.03 88% 72%–95% ,0.001 0.051
Self-report (3) 2.26 0.82–6.23 73% 9%–92% 0.025 0.692
Medical records (6) 1.61 1.33–1.95 85% 69%–93% ,0.001 Ref
TB diagnosis Microbiological (4)
h 4.91 3.41–7.06 63% 0%–87% 0.045 0.015
Other (9) 1.66 1.39–1.98 79% 61%–89% ,0.001 —
Control selection (case-
control studies)
Nested or population-based (4) 3.36 1.52–7.42 84% 59%–94% ,0.001 0.321
Hospital or discharge data based (3) 1.62 1.54–1.72 0% 0%–90% 0.920 —
Adjustment factors Ageþsex (10) 2.25 1.59–3.19 96% 94%–97% ,0.001 N/A
Ageþsexþrace (7)
i 2.05 1.35–3.12 97% 96%–98% ,0.001 N/A
Ageþsexþimmunosuppressive drugs (4) 2.37 1.45–3.87 76% 34%–91% 0.006 N/A
Ageþsexþalcohol (3) 3.51 1.10–11.23 78% 30%–93% 0.010 N/A
Ageþsexþsocioeonomic status (3) 1.66 1.45–1.91 71% 0%–91% 0.033 N/A
Ageþsexþsmoking (2) 4.40 2.49–7.29 17% 0%–57% 0.272 N/A
Potential for duplicate
data on same patient
No (11) 2.60 1.62–4.18 95% 93%–97% ,0.001 0.324
Yes (2) 1.62 1.53–1.72 0% N/A
j 0.683 —
RR indicates risk ratio, hazard ratio, or odds ratio.
aPercentage of total variance due to between-study heterogeneity.
bp-Value for Cochrane Q test of heterogeneity within subgroup.
cp-Value for the difference in ln(RR) from meta-regression weighting the studies by the inverse of the sum of within and between-study variance.
dBackground TB incidence per 100,000 person-years.
eResults for analysis restricted to Hispanics in the two US studies by Pablos-Mendez et al. [8] and Perez et al. [11].
fMeta-regression p-values for these three rows are for comparison within the North American studies.
gResults for analysis restricted to American Indians in studies by Mori et al. [34] and Dyck et al. [25].
hPositive for acid-fast bacilli in sputum, or for M. tuberculosis in culture; includes results for culture positive or smear-positive TB from Kim et al. [7].
iIncludes studies that had adjusted for race, as well as studies with ethnically homogeneous populations.
jTest-based confidence interval for I
2 ¼ 0% with one degree of freedom could not be computed with STATA or manually.
N/A, not applicable.
doi:10.1371/journal.pmed.0050152.t002
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Diabetes and Tuberculosis Review(trend pKim ¼ 0.014, pPonce-de-Leon ¼ 0.184). Each 10 y increase
in age was associated with a 0.6-fold reduction in magnitude
of association in the study by Kim et al. [7]. This trend was not
apparent in the study by Dyck et al. (Figure 3) [25].
Both the Egger test and Begg test for publication bias were
insigniﬁcant (p ¼ 0.37, p ¼ 0.14).
Discussion
Summary of Findings
Our meta-analysis shows that DM increases the risk of TB,
regardless of different study designs, background TB inci-
dence, or geographic region of the study. The cohort studies
reveal that compared with people who do not have diabetes,
people with diabetes have an approximately 3-fold risk of
developing active TB. Higher increases in risk were seen
among younger people, in populations with high background
TB incidence, and in non-North American populations.
Heterogeneity of strengths of association may reﬂect true
geographic/ethnic differences in severity of DM, transmission
dynamics of TB, and the distribution of effect modiﬁers such
as age, or it may be due to differences in study methodology
or rigor. Given this heterogeneity of the RR estimates and the
fact that all the cohort studies were conducted in Asia, we
note that the summary estimate may not be applicable to
other populations and study types. While the included studies
covered a relatively broad range of geographic areas, there
were none from Africa, where TB incidence is high. None-
theless, a positive association of DM and TB was noted in two
African studies [38,39] and several other studies that we
excluded from the meta-analysis [10,40–42], as well as in a
previous narrative review [43] of the association of DM and
TB. Unlike the previous review, our systematic review
identiﬁed ﬁve additional studies that had examined the
association of DM and TB, computed a pooled summary
estimate among the cohort studies, and determined impor-
tant sources of heterogeneity through rigorous sensitivity
analyses.
Public Health Implication
With an estimated 180 million people who have diabetes, a
ﬁgure expected to double by year 2030, it is clear that DM
constitutes a substantial contributor to the current and
future global burdens of TB. For example, if we assume a RR
of 3 and a prevalence of DM in Mexico of 6%, we can
conclude that DM accounts for 67% of active TB cases among
people with diabetes, and 11% of cases among the entire
Mexican population (see Text S1 for the calculation) [44]. The
contribution of DM to the burden of TB may be even higher
in countries such as India and China where the incidence TB
is greater and mean age is lower. In fact, a recent study by
Stevenson et al. determined that DM accounts for 80.5% of
Figure 3. Forest Plot of Age-Specific Association between Diabetes and Active Tuberculosis from Kim et al. [7], Ponce-de-Leon et al. [9], and Dyck et al.
[25]
Size of the square is proportional to the precision of the study-specific effect estimates, and the bars indicate 95% CI of the effect estimates. Arrows
indicate that the bars are truncated to fit the plot. *Meta-regression: Factor reduction in RR with 10 y increase in age; p-values are given for test of linear
trend. HR, hazard ratio.
doi:10.1371/journal.pmed.0050152.g003
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14.8% of incident TB in the total population in India [16].
The population-attributable risk for diabetes is comparable
to that of HIV/AIDS; while HIV/AIDS is strong risk factor for
TB (RRHIV ¼ 6.5–26 [45], approximately 2–9 times greater
than the RRDM estimated in this study), it is a less prevalent
medical condition (33 million people infected in 2007 [46],
approximately 5–6 times less prevalent than DM). Given these
ﬁgures it may be puzzling to observe a decrease in TB in those
areas that have experienced a growing burden of DM. We
attribute this observation to negative confounding by factors
such as improved nutrition and TB control measures in the
areas of increasing DM such as India and China. Were these
other factors to remain the same, we would expect to see a TB
incidence trend reﬂecting that of DM in accordance with the
positive association.
Biological Plausibility
Numerous studies have presented convincing biological
evidence in support of the causal relationship between DM
and impaired host immunity to TB. Studies in animal models
have demonstrated that diabetic mice experimentally infected
with M. tuberculosis have higher bacterial loads compared to
euglycemic mice, regardless of the route of inoculation of M.
tuberculosis [47,48]. Compared to euglycemic mice, chronically
diabetic mice also had signiﬁcantly lower production of
interferon-c (IFN-c) and interleukin-12 (IL-12) and fewer M.
tuberculosis antigen (ESAT-6)-responsive T cells early in the
course of M. tuberculosis infection, marking a diminished T
helper 1 (Th1) adaptive immunity, which plays a crucial role
in controlling TB infection [48]. In experimental studies of
human plasma cells, high levels of insulin have been shown to
promote a decrease in Th1 immunity through a reduction in
the Th1 cell to Th2 cell ratio and IFN-c to IL-4 ratio [49].
Additionally, an ex vivo comparison study of production of
Th1 cytokines showed that nonspeciﬁc IFN-c levels were
signiﬁcantly reduced in people with diabetes compared to
controls without diabetes [50]. Another study indicated a
dose–response relationship; levels of IFN-c were negatively
correlated with levels of HbA1c (a measure of serum glucose
levels over time in humans) [51]. Furthermore, neutrophils
from people with diabetes had reduced chemotaxis and
oxidative killing potential than those of nondiabetic controls
[52], and leukocyte bactericidal activity was reduced in people
with diabetes, especially those with poor glucose control [53].
Taken together, these studies strongly support the hypothesis
that DM directly impairs the innate and adaptive immune
responses necessary to counter the proliferation of TB.
Limitations
There are several potential limitations to this study. Our
analysis was based on estimates derived from observational
studies that are vulnerable to confounding by variables
associated with both DM and TB. To address the issue of
potential confounding, we performed a sensitivity analysis in
which we reported separate summary estimates for the
studies that adjusted for important potential confounders
and those that did not. Studies that controlled for socio-
economic status in a multivariable model found that the
adjusted effect of DM was reduced, but not eliminated. Crude
effect estimates were not provided in two of the larger studies
that adjusted for socioeconomic status, thus the direction of
bias cannot be determined. The three studies that did report
both crude and the adjusted estimates [33,34,37] found that
the adjusted RRs for DM were higher. Although we could not
exclude the possibility of residual confounding by unmeas-
ured confounders in these observational studies, such as
other chronic diseases that often coexist with diabetes, we
found that the effect of DM on TB risk persisted even after
adjustment for multiple potential confounders that are likely
to be correlated with unmeasured factors.
Eight of the studies included in this meta-analysis were
case-control studies. Control selection strategies included
sampling from hospitals, discharge records, department of
health records, the general population, and the cohort in
which the study was nested. Sampling controls from hospital
or discharge records may have introduced a Berkson bias—a
selection bias that can occur when both the exposure and the
outcome are associated with attendance at a health-care
facility from which cases and controls are recruited [54].
Since DM can lead to multiple health problems, the
prevalence of DM is likely to be higher among persons
attending clinics or being admitted to hospitals than it is in
the general population. This bias would be expected to result
in an underestimation of the effect of DM on TB, an
expectation that was consistent with our ﬁnding that studies
using hospital-based controls reported lower effect estimates
[54]. Other sources of potential bias include misclassiﬁcation
of either exposure or outcome, such as may have occurred in
studies that did not employ laboratory tests to diagnose DM
or TB. When we restricted our analysis to studies that used
glucose tests to determine DM status, we found that effect
estimates were higher than in the studies that relied on less-
rigorous methods, consistent with our expectation of a bias
toward the null among studies that nondifferentially mis-
classify the exposure. Studies that utilized glucose tests to
classify the exposure may also have reported higher RRs of
TB among people with diabetes, since they may have
identiﬁed undiagnosed people with diabetes who remained
untreated and therefore may have had higher glycemic levels
that those who self-reported their status. Those studies that
conﬁrmed TB through microbiological diagnosis also re-
ported stronger associations, suggesting that diabetes may
have a stronger impact on smear-positive and thus trans-
missible forms of TB. Our result underscores the conclusion
by Stevenson et al. that DM accounts for a greater proportion
of smear-positive TB than of other forms [17]. In short, we
found that magnitudes of association varied by the quality of
the studies; at the same time, variations may have been
inﬂuenced by differences in population characteristics that
are correlated with quality-associated variables.
Another important limitation of our systematic review is
that most of the studies we included failed to examine age as
an effect modiﬁer of the relationship between DM and TB.
The studies by Kim et al. [7] and Ponce-de-Leon et al. [9]
found that estimates varied markedly by age, with substan-
tially higher estimates among younger people. This ﬁnding
may be explained by heterogeneity of the individuals without
diabetes between the age groups. Because baseline glucose
tolerance is lower in older persons without diabetes, elderly
controls may have had an elevated risk of TB compared to
younger ones [55], thus reducing the apparent effect of DM. It
is possible that younger people with diabetes might have had
type I diabetes, a more severe form of diabetes with a juvenile
PLoS Medicine | www.plosmedicine.org July 2008 | Volume 5 | Issue 7 | e152 1099
Diabetes and Tuberculosis Reviewonset; however, because most studies did not distinguish
between type I and type II diabetes we cannot conclude
whether the effect modiﬁcation by age would have been due
to differences in types of diabetes. Notably, the study by Dyck
et al. [25] did not demonstrate this trend in the age-speciﬁcity
of the effect of DM on TB and in fact showed a negative
association among the elderly. The authors of the study note
that results may have been biased by differential mortality in
the elderly since individuals with diabetes who would have
been most at risk for TB would have already died. Moreover,
this study also differed from the others in that it relied on
medical records rather than laboratory tests to determine DM
status, and it had not included DM occurring in the last six of
the 16 y during which TB case accrual occurred.
Conclusions
In summary, we found consistent evidence for an increased
risk of TB among people with diabetes despite heterogeneity
in study design, geographic area, underlying burden of TB,
assessment of exposure and outcome, and control of
potential confounders. Data from these human studies are
consistent with emerging information on the biological
mechanisms by which hyperglycemia may affect the host
immune response to TB. Our ﬁndings suggest that TB
controls programs should consider targeting patients with
diabetes for interventions such as active case ﬁnding and the
treatment of latent TB and, conversely, that efforts to
diagnose, detect, and treat DM may have a beneﬁcial impact
on TB control. We also recommend further studies inves-
tigating how TB risk varies by type, duration, and severity of
DM, for a more thorough understanding of the association
that could be translated to a clear public health message.
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Editors’ Summary
Background. Every year, 8.8 million people develop active tuberculosis
and 1.6 million people die from this highly contagious infection that
usually affects the lungs. Tuberculosis is caused by Mycobacterium
tuberculosis, bacteria that are spread through the air when people with
active tuberculosis cough or sneeze. Most infected people never become
ill—a third of the world’s population is actually infected with M.
tuberculosis—because the human immune system usually contains the
infection. However, the bacteria remain dormant within the body and
can cause disease many years later if host immunity declines because of
increasing age or because of other medical conditions such as HIV
infection. Active tuberculosis can be cured by taking a combination of
several antibiotics every day for at least six months, and current control
efforts concentrate on prompt detection and carefully monitored
treatment of people with active tuberculosis to prevent further
transmission of the bacteria.
Why Was This Study Done? Despite this control strategy, tuberculosis
remains a major health problem in many countries. To reduce the annual
number of new tuberculosis cases (incidence) and the number of people
with tuberculosis (prevalence) in such countries, it may be necessary to
identify and target factors that increase an individual’s risk of developing
active tuberculosis. One possible risk factor for tuberculosis is diabetes, a
condition characterized by high blood sugar levels and long-term
complications involving the circulation, eyes and kidneys, and the body’s
ability to fight infection. 180 million people currently have diabetes, but
this number is expected to double by 2030. Low- to middle-income
countries (for example, India and China) have the highest burden of
tuberculosis and are experiencing the fastest increase in diabetes
prevalence. If diabetes does increase the risk of developing active
tuberculosis, this overlap between the diabetes and tuberculosis
epidemics could adversely affect global tuberculosis control efforts. In
this study, the researchers undertake a systematic review (a search using
specific criteria to identify relevant research studies, which are then
appraised) and a random effects meta-analysis (a type of statistical
analysis that pools the results of several studies) to learn more about the
association between diabetes and tuberculosis.
What Did the Researchers Do and Find? From their search of electronic
databases, the researchers found 13 observational studies (nonexper-
imental investigations that record individual characteristics and health
outcomes without trying to influence them in any way) that had
examined whether diabetes mellitus increases the risk of active
tuberculosis. Diabetes was positively associated with tuberculosis in all
but one study, but the estimates of how much diabetes increases the risk
of developing active tuberculosis were highly variable, ranging from no
effect to an increased risk of nearly 8-fold in one study. The variability
may represent true differences between the study populations, as higher
increases in risk due to diabetes was found in studies conducted outside
of North America, including Central America, Europe, and Asia; or it may
reflect differences in how well each study was done. This variability
meant that the researchers could not include all of the studies in their
meta-analysis. However, the three prospective cohort studies (studies
that follow a group of individuals with potential risk factors for a disease
over time to see if they develop that disease) that they had identified in
their systematic review had more consistent effects estimates, and were
included in the meta-analysis. This meta-analysis showed that, compared
to people without diabetes, people with diabetes had a 3-fold increased
risk of developing active tuberculosis.
What Do These Findings Mean? These findings support the idea that
diabetes increases the risk of tuberculosis, a biologically plausible idea
because, in experimental and clinical studies, diabetes was found to
impair the immune responses needed to control bacterial infections. The
3-fold increased risk of tuberculosis associated with diabetes that the
meta-analysis reveals suggests that diabetes may already be responsible
for more than 10% of tuberculosis cases in countries such as India and
China, a figure that will likely increase as diabetes becomes more
common.
However, the estimate of this impact is based on three cohort studies
from Asia; other studies suggest that the extent of the impact due to
diabetes may vary by region and ethnicity. In populations where
diabetes affects the risk of tuberculosis to a similar or greater extent,
global tuberculosis control might benefit from active case finding and
treatment of dormant tuberculosis in people with diabetes and from
increased efforts to diagnose and treat diabetes.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0050152.
  The US National Institute of Allergy and Infectious Diseases provides
information on all aspects of tuberculosis
  The US Centers for Disease Control and Prevention provide several fact
sheets and other information resources about tuberculosis
  The World Health Organization provides information (in several
languages) on efforts to reduce the global burden of tuberculosis,
including information on the Stop TB Strategy and the 2008 report
Global Tuberculosis Control—Surveillance, Planning, Financing
  The US Centers for Disease Control and Prevention provides
information for the public and professionals on all aspects of diabetes
  The US National Institute of Diabetes and Digestive and Kidney
Diseases also provides information about diabetes (in English and
Spanish)
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